Skip to main content

Advertisement

Table 1 Patients’ pre-treatment characteristics

From: Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia

Pre-FCR characteristics n (%) or median [min-max]
Gender
 •Men 112 (69.1)
 •Women 50 (30.9)
Age category
 •>65 years 58 (35.8)
 •≤65 years 104 (64.2)
Binet stage
 •Binet A 34 (21.3)
 •Binet B 85 (53.1)
 •Binet C 41 (25.6)
 •Missing 2
Time from diagnosis to FCR (months) 22.1 [0.03-203.00]
Lymphocytes (G/L) (n=114) 90.6 [1.30-888.0]
β2-microglobulin
 •≤3.5 mg/L 15 (21.7)
 •>3.5 mg/L 54 (78.3)
 •Missing 93
LDH value
 •LDH≤ULN 52 (45.6)
 •LDH>ULN 62 (54.4)
 •Missing 48
IGHV mutation status
 •IGHV-M 48 (36.6)
 •IGHV-UM 83 (63.4)
 •Missing 31
Del13q
 •Del13q 49 (37.4)
 •No del13q 82 (62.6)
 •Missing 31
Trisomy 12
 •Trisomy 12 32 (24.4)
 •No trisomy 12 99 (75.6)
 •Missing 31
Del11q
 •Del11q 34 (22.2)
 •No del11q 119 (77.8)
 •Missing 9
Del6q
 •Del6q 14 (12.8)
 •No del6q 95 (87.2)
 •Missing 53
t(14;18)(q32;q21)
 •t(14;18)(q32;q21) 5 (4.6)
 •No t(14;18)(q32;q21) 104 (95.4)
 •Missing 53
Del17p
 •Del17p 6 (3.9)
 •No del17p 146 (96.1)
 •Missing 10
Complex karyotype
 •Complex karyotype 87 (78.4)
 •No complex karyotype 24 (21.6)
 •Missing 51
TP53 mutation
 •TP53 mutation 2 (2.9)
 •No TP53 mutation 68 (97.1)
 •Missing 92
NOTCH1 mutation
 •NOTCH1 mutation 11 (16.2)
 •No NOTCH1 mutation 57 (83.8)
 •Missing 94
SF3B1 mutation
 •SF3B1 mutation 6 (8.8)
 •No SF3B1 mutation 62 (91.2)
 •Missing 94
MYD88 mutation
 •MYD88 mutation 1 (1.5)
 •No MYD88 mutation 66 (98.5)
 •Missing 95
BRAF mutation
 •No BRAF mutation 67 (100)
 •Missing 85